Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Screening for cancer: is it cost effective?

M K Schwartz1

  • 1Department of Clinical Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY 10021.

Clinical Chemistry
|November 1, 1993
PubMed
Summary

Cancer screening tests, like prostate-specific antigen (PSA), can identify potential risks in asymptomatic individuals. These markers help assess cancer probability and predict recurrence in treated patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sampling large geographic areas for rare species using environmental DNA: a study of bull trout Salvelinus confluentus occupancy in western Montana.

Journal of fish biology·2016
Same author

Estimation of effective population size in continuously distributed populations: there goes the neighborhood.

Heredity·2013
Same author

Development and evaluation of 200 novel SNP assays for population genetic studies of westslope cutthroat trout and genetic identification of related taxa.

Molecular ecology resources·2012
Same author

Why replication is important in landscape genetics: American black bear in the Rocky Mountains.

Molecular ecology·2011
Same author

Quantifying the lag time to detect barriers in landscape genetics.

Molecular ecology·2010
Same author

Behavioral and neurochemical phenotyping of Homer1 mutant mice: possible relevance to schizophrenia.

Genes, brain, and behavior·2005

Area of Science:

  • Oncology
  • Biochemistry
  • Preventive Medicine

Background:

  • Screening identifies unrecognized disease in populations or high-risk individuals.
  • Immunochemical and biochemical cancer markers function as risk-factor monitors.
  • Interpreting these markers differs for asymptomatic populations versus previously treated patients.

Purpose of the Study:

  • To evaluate cancer screening tests as risk-factor monitors.
  • To discuss the application of specific cancer markers in risk assessment.
  • To highlight the importance of contextual interpretation for cancer marker values.

Main Methods:

  • Review of existing screening successes (alpha-fetoprotein for hepatocellular carcinoma, catechol metabolites for neuroblastoma).
  • Focus on the potential use of CA 125 for ovarian cancer and prostate-specific antigen (PSA) for prostate cancer risk assessment.
  • Analysis of the probabilistic interpretation of cancer marker values in specific clinical contexts.

Main Results:

  • Successful screening examples demonstrate the utility of specific biochemical markers.
  • CA 125 and PSA show potential for risk-factor assessment in ovarian and prostate cancers, respectively.
  • A PSA value > 10 micrograms/L indicates a 67% probability of prostate cancer in a specific context.

Conclusions:

  • Cancer screening markers can be effectively used as risk-factor monitors.
  • Contextual interpretation is crucial for accurate risk assessment and prediction.
  • Further understanding of marker utility can improve early cancer detection and management.

Related Experiment Videos